Pharmacokinetic-pharmacodynamic model for perindoprilat regional haemodynamic effects in healthy volunteers and in congestive heart failure patients

British Journal of Clinical Pharmacology

Volumn 52, Issue 1, 2001, Pages 25-33

  Bellissant, Eric ^a,b   Giudicelli, Jean François ^a  

^a BICÊTRE HOSPITAL   (France)

^b Inst de Rech Contre le Cancer IRCC   (France)

Author keywords

Concentration effect relationship; Congestive heart failure patients; Effect compartment; Haemodynamics; Healthy volunteers; Perindopril; PK PD modelling; Sigmoid model

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PERINDOPRIL; PERINDOPRILAT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HEMODYNAMICS; HUMAN; HYSTERESIS; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASCULAR RESISTANCE;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BRACHIAL ARTERY; CARDIOVASCULAR AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; INDOLES; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; PERINDOPRIL; VASCULAR RESISTANCE;

EID: 0034819244     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0306-5251.2001.01410.x     Document Type: Article

References (32)

1. Pharmacodynamic modelling. Application to new drug development
2. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development
3. Predictability of antihypertensive responsiveness and α-adrenoceptor antagonism during prazosin treatment
4. Kinetic-dynamic relations and individual responses to enalapril
5. Pharmacodynamic modeling of the antihypertensive response to amlodipine
6. Pharmacokinetic and pharmacodynamic modelling of trimazosin and its major metabolite
7. Nifedipine: Kinetics and dynamics in healthy subjects
8. Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: Development of a mathematical model
9. Débits cardiaque et régionaux non invasifs chez le volontairesain. Intérét prédictif
10. Dose-response clarification in early drug development
11. Plasma concentration-effect relationship of felodipine intravenously in patients with congestive heart failure
12. Pharmacokinetic-pharmacodynamic model relating spiraprilat plasma concentrations to systemic and regional hemodynamic effects in congestive heart failure
13. Angiotensinergic versus nonangiotensinergic hemodynamic effects of converting enzyme inhibition in patients with chronic heart failure. Assessment by acute renin and converting enzyme inhibition
14. Blood pressure control by the renin-angiotensin system in normotensive subjects. Assessment by angiotensin converting enzyme and renin inhibition
15. Perindopril. A review of its pharmacological properties and therapeutic use in cardiovascular disorders
16. Perindopril, converting enzyme blockade, and peripheral arterial hemodynamics in the healthy volunteer
17. Systemic and regional hemodynamic effects of perindopril in congestive heart failure
18. Pulsed Doppler: Diameter, blood flow velocity and volumic flow of the brachial artery in sustained essential hypertension
19. Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung
20. Radioimmunoassay of a new angiotensin-converting enzyme inhibitor (perindopril) in human plasma and urine: Advantages of coupling anion-exchange column chromatography with radioimmunoassay
21. A computer program for kinetic-dynamic modeling in non steady-state experiments
22. Pharmacokinetic-pharmacodynamic model relating lisinopril plasma concentrations to regional hemodynamic effects in healthy volunteers
23. Methodological issues in pharmacokinetic-pharmacodynamic modelling
24. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine
25. Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models
26. Simultaneous modeling of pharmacokinetics and pharmacodynamics with a nonparametric pharmacodynamic model
27. Pharmacokinetic-pharmacodynamic model for fantofarone cardiac and brachial haemodynamic effects in healthy volunteers
28. Effect of repeated dosing on concentration-effect relationships with the angiotensin converting enzyme inhibitor, perindopril
29. Pharmacokinetic-pharmacodynamic model relating zabiciprilat plasma concentrations to brachial and femoral haemodynamic effects in normotensive volunteers
30. Placebo-controlled, randomized, double-blind study of intravenous enalaprilat efficacy and safety in acute cardiogenic pulmonary edema